Sept 8 (Reuters) - Genmab A/S:
* GlaxoSmithKline and Genmab announce start of Ofatumumab Phase III combination study in non-Hodgkin's Lymphoma
* Says co will receive a milestone payment of about $20 million
* Says co will receive a milestone payment from GlaxoSmithkline
* Says milestone payment triggered by the treatment of the first patient in the
study
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* GlaxoSmithKline and Genmab announce start of Ofatumumab Phase III combination study in non-Hodgkin's Lymphoma
* Says co will receive a milestone payment of about $20 million
* Says co will receive a milestone payment from GlaxoSmithkline
* Says milestone payment triggered by the treatment of the first patient in the
study
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.